News | May 18, 2009

Biotronik IMPACT Study Examines Remote Monitoring to Reduce Risk of Stroke in AF Patients

May 18, 2009 – At Heart Rhythm 2009 last week Biotronik said it completed the first enrollment in the pivotal phase of its IMPACT clinical study, which investigates whether the risk of stroke can be reduced in patients being treated for atrial fibrillation with cardiac devices through early detection of these arrhythmias.

The IMPACT study is an international clinical trial using Biotronik’s remote monitoring technologies in conjunction with its Lumax HF-T and DR-T defibrillators and a predefined anticoagulation plan. The devices can be used with Biotronik’s Home Monitoring, which provides the physicians with automatic, remote updates on their patients’ cardiovascular and device status.

The IMPACT study began in 2008 with the technical feasibility phase, which included 227 patients and 27 sites. The pivotal phase, the next stage of the study, will include up to 100 sites and 2,700 patients randomized to the study.

"IMPACT is a unique study,” said Albert L. Waldo, M.D., professor of medicine and professor of biomedical engineering at Case Western Reserve University in Cleveland, Ohio. “By using Biotronik Home Monitoring capabilities, the medical community has the potential to change how we administer anticoagulants in patients with atrial tachycardia, who are at risk for stroke." Dr. Waldo is a member of the IMPACT Steering Committee.

“Through the IMPACT study, we hope to gain insight for optimal treatment of patients with atrial fibrillation and heart failure,” said John J. Ip, M.D., electrophysiologist at the Thoracic and Cardiovascular Health Care Foundation in East Lansing, Mich., and IMPACT Steering Committee co-chairman. “By using device data with the Biotronik Home Monitoring system, it may be possible to record and interpret the timing of atrial fibrillation and efficacy of early anticoagulation therapy in an aging population.”

For more information, visit

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Overlay Init